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ABSTRACT 
Background and Objectives: The purpose of this study was to investigate 1) the beneficial effect of bosentan 
treatment (125 mg twice daily) on exercise capacity and echocardiographic variables and 2) the profiles and 
frequency of adverse events in Korean patients with World Health Organization (WHO) class III or IV pulmonary 
artery hypertension (PAH). Subjects and Methods: Twelve patients who received bosentan treatment were investi-
gated in an open label manner. One patient was excluded in the final analyses due to a prohibited concomitant 
medication. A 6-minute walk test and echocardiography were performed at baseline and after 12 weeks of treat-
ment. Results: The administration of bosentan for 12 weeks resulted in a significant improvement in exercise 
capacity (measured with the 6-minute walking distance), WHO functional capacity, and in echocardiographic 
variables. Bosentan treatment was associated with a decrease in the maximal tricuspid regurgitation jet velocity 
{from 4.7 m/sec (95% confidence interval, 3.89-5.45) at baseline to 4.4 m/sec (95% confidence interval, 3.61-
5.1) at 12 weeks, p=0.03} and systolic pulmonary arterial pressure {from 105 mmHg (95% confidence interval, 
74.4-135.6) at baseline to 93 mmHg (95% confidence interval, 66.3-120.1) at 12 weeks, p=0.04}. Treatment with 
bosentan at a dose of 125 mg twice a day was not associated with life-threatening side effects, although a higher 
incidence of elevated liver enzymes compared to previous studies was noted. Conclusion: Bosentan at a dose of 
125 mg twice daily is considered a clinically optimal, safe dose and can be used as a valuable treatment option in 
Korean PAH patients with WHO functional capacity III or IV, though close monitoring of liver function is 
required. (Korean Circ J 2009;39:105-110) 
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Introduction 
 
Pulmonary artery hypertension (PAH) is a devastating 
condition that is characterized by a progressive increase 
in pulmonary vascular resistance, ultimately leading to 
right heart failure and death.1) To date, the prognosis 
for patients with PAH is poor due mainly to the limited 
treatment options. The estimated median survival time 
is 2.8 years and the estimated 1-, 3-, and 5-year survival 
rates are 68%, 48%, and 34%, respectively, in patients 
treated with conventional medications, such as high-
dose calcium-channel blockers and prostanoids.2) 
Endothelin-1 (ET-1) is a 21-amino-acid, generated 
from big endothelin by endothelin-converting enzymes 
in endothelial cells. It is known to have potent effects 
on vasoconstriction, mitosis, and cell proliferation.3)4) 
The ET-1 concentrations are increased in the tissues 
and plasma of patients with PAH due to a reduction in 
clearance in the pulmonary vascular bed.5) An elevated 
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ET-1 concentration is strongly correlated with disease 
severity and prognosis in PAH,6) all of which suggest a 
pathogenic role of ET-1 in PAH. Previous clinical trials 
using bosentan have clearly demonstrated improvements 
in pulmonary hemodynamics and exercise tolerance in 
patients with PAH, supporting its use as a therapeutic 
strategy for PAH.4-9) European and US treatment guide-
lines have incorporated bosentan as a treatment option 
for PAH patients according to World Health Organiza-
tion (WHO) functional class.10-12)  
Bosentan was recently approved for PAH treatment 
in Korea. However, its beneficial effects on PAH have 
not been clinically proven in Korean patients. Therefore, 
the objective of this study was to investigate the effect 
of bosentan on exercise capacity and pulmonary hemo-
dynamics measured by echocardiography in Korean PAH 
patients with WHO class III or IV. We also evaluated 
the profile and the frequency of adverse events related 
to bosentan treatment. 
 
Subjects and Methods 
 
Study population 
Patients with PAH over 12 years of age were enrolled 
into the study if they met the following criteria: 1) symp-
tomatic, severe idiopathic PAH (IPAH), PAH due to 
collagen vascular disease (e.g., mixed connective tissue 
disease, systemic lupus erythematosus, or systemic scle-
rosis), or PAH due to congenital heart disease with pre-
vious surgical correction, 2) functional class III or IV 
according to the 1998 WHO classification, despite max-
imal conventional medical therapy, and 3) a baseline 
6-minute walking distance between 150 and 500 m. In 
addition to these criteria, the following hemodynamic 
variables measured at right heart catheterization within 
3 months prior to recruitment must also be fulfilled; 
mean pulmonary arterial pressure (mPAP) >25 mmHg 
at rest by right heart catheterization, pulmonary capil-
lary wedge pressure (PCWP) <15 mmHg, and pulmonary 
vascular resistance (PVR) >3 mmHg/L/min. The inva-
sive right heart catheterization was performed at the 
screening visit only for patients who had no hemo-
dynamic confirmation of PAH within 3 months of en-
rollment. Due to the teratogenic nature of bosentan, pa-
tients who had a possibility of pregnancy were excluded. 
Patients who had taken phosphodiesterase V inhibitors, 
such as sildenafil, vardenafil, or tadalafil, within 1 month 
before enrollment were also excluded. The local ethics 
committees approved the protocol and written informed 
consent was obtained from all patients. 
 
Echocardiographic measurements 
Transthoracic echocardiography was also performed 
at the screening visit, 4 week thereafter (if necessary), 
and the end of the study or after premature discontinu-
ation from the study. Right heart catheterization and 
the initial echocardiographic examination were per-
formed within 5-8 days of one another, with a mean 
interval of 0.5±3.3 days. The right ventricular (RV) end-
diastolic and end-systolic areas were carefully measured 
in the apical 4-chamber view to estimate the RV per-
centage area change using the following formula:13) RV 
percentage area change=(RV end-diastolic area-RV end-
systolic area)/RV end-diastolic area×100. The RV per-
centage area change is known to be the best indicator 
of RV systolic function.13)14) The left ventricular (LV) 
outflow tract (LVOT) diameter (D; in cm) was measured 
at the level of the aortic annulus from inner edge to in-
ner edge, utilizing a zoomed image from the parasternal 
long-axis view, from which the cross-sectional area of 
the LVOT (CSALVOT) was calculated using the formula: 
CSALVOT=3.14×(D/2)2. From the apical 5-chamber 
view, the LVOT time velocity integral (LVOT TVI; in 
cm) was obtained by positioning the sample volume of 
the pulsed wave Doppler at the LVOT. The cardiac out-
put (CO) was determined from the pulsed wave measure-
ments of the LVOT velocity profile as follows: CO= 
CSALVOT×LVOT TVI×heart rate. The cardiac index 
(CI; in L/min/m2) was calculated by dividing the car-
diac output by the body surface area (BSA) of the patient 
(CI=CO/BSA). The maximal tricuspid regurgitation 
velocity (TR Vmax; in cm/sec) was obtained from con-
tinuous-wave Doppler of the TR signal. The Doppler-
derived systolic pulmonary artery pressure (sPAP; in 
mmHg) was then calculated from the maximal TR Vmax 
using the simplified Bernoulli formula as follows: sPAP 
=4×(TR Vmax)2+right atrial pressure (RAP). RAP 
was estimated by the response of the inferior vena cava 
to deep inspiration.15)  
In the presence of pulmonary regurgitation (PR), the 
mean pulmonary artery pressure (mPAP) was estimated 
from the maximal PR velocity (PR Vmax) using the sim-
plified Bernoulli formula as follows: mPAP=4×(PR 
Vmax)2+RAP. 
 
Bosentan administration and serial follow-up 
After obtaining baseline measurements, bosentan ad-
ministration was launched at a dose of 62.5 mg twice 
daily for 4 weeks, and 125 mg twice daily for the subsequ-
ent 8 weeks. Safety was assessed on the basis of recorded 
adverse events, clinical laboratory parameters, vital signs, 
and electrocardiography. The efficacy of bosentan treat-
ment was assessed by changes in the 6-minute walking 
distance and the WHO functional class after 4 and 8 
weeks of treatment, and at the end of study visit or after 
premature discontinuation from the study.  
 
Statistical analysis 
All values are expressed as the mean±SD or as a num-
ber (percentage). Parameters obtained at the 12-week 
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visit were compared to the corresponding baseline values 
with the Wilcoxon signed-rank sum test. All statistical 
analyses were performed using Statistical Package for 
Social Science (SPSS) 13.0 (SPSS Inc., Chicago, IL, USA), 
and a p<0.05 was considered statistically significant. 
  
Results 
 
Baseline characteristics of the study population 
Twelve patients were recruited from six centers. One 
patient was excluded from the efficacy analysis owing 
to a prohibited concomitant medication (tadalafil). Th-
erefore, the efficacy analyses were completed in 11 pa-
tients, whereas safety profiles were analyzed based on 
all 12 patients.  
The baseline characteristics of the 12 patients are shown 
in Table 1. All patients were in WHO functional class 
III at baseline. The causes of PAH were idiopathic in 
nine patients, collagen vascular disease in two patients, 
and corrected congenital heart disease in one patient. 
The pulmonary hemodynamic data in these patients are 
shown in Table 1. 
 
Correlation between echocardiography and cath-
eterization in terms of systolic pulmonary artery 
pressure measurement 
The values of sPAP obtained by Doppler echocardio-
graphy were highly correlated with the values obtained 
at the right heart catheterization (Spearman’s r=0.85, 
p=0.001, n=11) (Fig. 1). The mean difference in sPAP 
between echocardiography and invasive catheterization 
measurements was 2.8±18.6 mmHg. 
 
Echocardiographic efficacy of bosentan therapy 
The changes in Doppler echocardiographic values at 
baseline and during treatment are summarized in Ta-
ble 2. In comparison with previously published echo-
cardiographic data in normal subjects,16)17) the patients 
with PAH in the present study had a severely dilated 
Table 2. Effect of bosentan on hemodynamic parameters measured by Doppler-echocardiography from baseline to the 12-week follow-up
Hemodynamic parameters* N Baseline; mean (95%CI) 12-week; mean (95%CI) p 
sPAP (mmHg) 11 105 (74.41, 135.59) 93 (66.29, 120.07) >0.04 
TR Vmax (m/sec) 11 4.7 (389.43, 545.12) 4.4 (361.00, 510.45) >0.03 
mPAP (mmHg) 09 56.7 (35.02, 78.31) 51.7 (34.44, 68.89) >0.45 
PR Vmax (m/sec) 08 2.9 (253.98, 335.02) 2.8 (237.56, 320.44) >0.64 
RV end-diastolic area (cm²) 09 30.3 (22.88, 37.65) 27.7 (21.18, 34.20) >0.12 
RV end-systolic area (cm²) 09 22.5 (15.39, 29.54) 20.7 (13.47, 27.89) >0.13 
RV percentage area change (%) 09 26.6 (18.72, 34.40) 27.3 (18.66, 36.00) >0.99 
LVOT diameter (cm) 11 3.08 (0.31, 5.85) 3.09 (0.43, 5.75) >0.88 
LVOT TVI (cm) 10 18.57 (15.74, 21.40) 20.89 (17.37, 24.41) >0.06 
Cardiac output (L/min) 10 3.6 (3.12, 3.97) 3.9 (2.93, 4.95) >0.28 
Cardiac index (L/min/m²) 10 2.3 (2.00, 2.62) 2.6 (1.89, 3.26) >0.23 
*By echocardiography. CI: confidence interval, sPAP: systolic pulmonary arterial pressure, TR Vmax: maximal tricuspid regurgitation velo-
city, mPAP: mean pulmonary arterial pressure, PR Vmax: maximal pulmonary regurgitation velocity, RV: right ventricle, LVOT: left ventri-
cular outflow tract, TVI: time velocity integral 
 
Table 1. Baseline demographics 
Variables N=12 
Female, n (%) 11 (91.7) 
Age (year) 31.2±14.4 
Body weight (kg) 53.45±6.82 
IPAH/Secondary PAH, n (%) 9 (75.0)/3 (25.0) 
WHO functional class III, n (%) 12 (100) 
6-minute walking distance (m) 350.5±73.4 
Pulmonary hemodynamics by RHC  
sPAP (mmHg ) 102.0±44.8* 
mPAP (mmHg) 63.8±25.2 
CI (L/min) 2.58±0.73 
PVR (dyne-sec-cm-5) 1101.3±553.2 
*n=11. IPAH: idiopathic pulmonary arterial hypertension, WHO:
World Health Organization, RHC: measured with right heart ca-
theterization, sPAP: systolic pulmonary arterial pressure, mPAP:
mean pulmonary arterial pressure, CI: cardiac index, PVR: pul-
monary vascular resistance 
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Fig. 1. Correlation between measurement of systolic pulmonary 
arterial pressure (sPAP) by right heart catheterization and Dop-
pler echocardiography (n=11). 
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RV. After 12 weeks of bosentan treatment, RV end-sys-
tolic and end-diastolic areas tended to decrease, but with-
out reaching statistical significance (p=0.12 and 0.13, 
respectively). RV systolic function, as evidenced by RV 
percentage area change, was not modified with bosentan 
treatment (p>0.99). Whereas sPAP derived from the 
TR Vmax displayed a significant reduction with bosen-
tan treatment (p=0.04 for sPAP and p=0.03 for TR 
Vmax), the mPAP estimated from the PR Vmax did 
not show a significant change (p=0.45 for mPAP and 
p=0.64 for PR Vmax). The CI trended toward an in-
crease with bosentan therapy (p=0.23). 
 
Clinical efficacy of bosentan therapy 
At the beginning of therapy, all 11 patients were WHO 
class III. After 4 weeks of therapy, 7 patients improved 
from class III to class II (p=0.02). At the last follow-up, 
6 patients became WHO class II, and 1 patient improved 
to WHO class I (p=0.02), whereas 4 patients remained 
WHO class III (Fig. 2). 
After 12 weeks of bosentan treatment, the 6-minute 
walking distance significantly increased from 350.5 m 
to 412.6 m (p=0.005) (Fig. 3).  
Safety and tolerability 
There were no deaths in relation to bosentan treat-
ment during the study period. There was also no clini-
cally significant change in systemic blood pressure. Over-
all, bosentan at a dose of 125 mg twice daily, was well 
tolerated. Regarding the adverse drug reactions related 
to bosentan treatment, a moderate headache requiring 
a transient interruption of bosentan treatment was ob-
served in 1 patient (8.3%), and increases in serum ami-
notransferase levels were noted in 2 patients (16.7%). 
In these two patients, the aminotransferase levels return-
ed to the baseline value with a reduction of bosentan 
dose in one patient, and the other patient showed a 
marked increment in aminotransferase values to >8 x 
the upper limit of normal after 6 weeks of bosentan treat-
ment, which normalized after cessation of bosentan. 
 
Discussion 
 
Results of previous trials with bosentan 
administration 
In Korea, the drugs approved for PAH treatment in-
clude iloprost inhalation, oral beraprost, and the oral ET 
receptor antagonist, bosentan. Of these medications, ac-
cording to the modified 2007 American College of Chest 
Physician guidelines, the ET receptor antagonist is re-
commended as a first-line therapy in patients with WHO 
functional class III, together with iloprost inhalation.18) 
Recent studies conducted in Western countries suggest 
that bosentan also offers a long-term therapeutic strat-
egy for the treatment of PAH. Bosentan monotherapy 
for patients with idiopathic PAH resulted in estimated 
1- and 2- year survival rates of 85% and 70%, respecti-
vely.10) Furthermore, the estimated 1- and 2-year surviv-
al rates of patients with WHO class III idiopathic PAH, 
who were actively treated with oral bosentan as a first-
line therapy, did not differ from those of an historical 
cohort of patients initiated on intravenous epoproste-
nol.19) Of note, ethnic differences have not been report-
ed with respect to the pharmcokinetics of bosentan. In 
this context, it has been reported that a dose adjustment 
is not required to treat the Asian PAH population with 
reference to Caucasians. In one study, a significant im-
provement in cardiopulmonary hemodynamics, symp-
toms, and functional capacity over a 12-week treatment 
with bosentan (125 mg twice daily) wasclearly demon-
strated for Japanese patients with severe PAH.20) A re-
cent long-term study (>2.5 years) conducted in Japan 
also showed that bosentan is associated with sustained 
clinical improvement.21) 
 
Echocardiography for a serial assessment  
of changes in pulmonary artery pressure 
Echocardiography is a well-established diagnostic ap-
proach for estimation of sPAP and mPAP. The values of 
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sPAP and mPAP obtained by Doppler echocardiogra-
phy are known to be highly correlated with values ob-
tained by invasive catheterization.22) This is further sup-
ported by the current study, as demonstrated in Fig. 1, 
with a correlation coefficient of 0.85 despite the lack 
of simultaneous measurement. Due to the limitation 
of invasive catheterization in serial evaluation of sPAP 
and mPAP, we employed tricuspid and pulmonary re-
gurgitation obtained by Doppler echocardiography to 
serially evaluate sPAP and mPAP during the follow-up 
period. Given the high concordance between values by 
Doppler echocardiography and invasive catheterization 
and the ethical dilemma in the serial performance of 
invasive catheterization solely for study purposes, our 
approach for the non-invasive evaluation of pulmonary 
artery pressure utilized in this study was rational and 
reasonable.  
 
Effect of bosentan therapy on clinical and echo-
cardiographic variables 
The current study is the first multicenter study in 
Korea that was designed to evaluate the beneficial and 
adverse effects of bosentan treatment for patients with 
PAH. The administration of bosentan for 12 weeks led 
to a significant improvement in exercise capacity and 
WHO classification. The magnitude of improvement in 
exercise capacity and WHO functional classification was 
greater than or similar to previous reports.8)23) With re-
spect to echocardiographic variables, with 12 weeks of 
bosentan therapy, a decrease in TR Vmax and sPAP was 
noted; however, mPAP that was derived from the PR 
Vmax was not statistically significant, despite a trend 
toward a decrease in absolute terms. Although the dis-
crepancy between the change in sPAP and mPAP can-
not be clearly explained based on the current study, we 
suggest that either the small number of patients en-
rolled in this study or a slight increment in diastolic PAP 
might be responsible. Future research should include 
data on diastolic PAP to resolve this question. Apart 
from mPAP, the RV end-diastolic and end-systolic areas, 
LVOT TVI, and the CI were not affected by bosentan 
administration over the 12-week study period. An ear-
lier study also showed a trend toward a decrease in RV 
end-systolic and end-diastolic areas with oral bosentan 
treatment without achieving statistical significance,24) 
which is in agreement with the results of the current 
study. In spite of a significant decrement in sPAP, bos-
entan treatment only showed a small increment in the 
CI. Because pulmonary artery pressure is determined 
by both pulmonary vascular resistance and pulmonary 
blood flow, a significant reduction in sPAP accomp-
anied only by a trend toward an increase in the CI sh-
ould imply that a gradual increase in pulmonary blood 
flow is preceded by a bosentan-induced decrease in pul-
monary vascular resistance. A more lengthy follow-up 
period may allow for detection of a significant increase 
in the CI. 
 
Adverse events with bosentan treatment 
Treatment with 125 mg of bosentan twice a day was 
not associated with any life-threatening adverse events; 
however, a significant proportion of patients experi-
enced an elevation in aminotransferase levels (16.7%), 
which is greater than the previous data reporting ab-
normal hepatic function to be only 4% on the same bo-
sentan dose. Nevertheless, an elevation in aminotrans-
ferase levels did not necessitate premature termination 
of bosentan treatment during the study period in any 
of the patients enrolled, and the abnormal elevation of 
liver enzymes gradually improved only with a dosage 
adjustment of bosentan. Thus, precautionary measures, 
such as periodic monitoring of aminotransferase levels, 
should be accompanied by the initiation of bosentan 
treatment to detect this adverse event. 
 
Conclusions 
Korean patients with severe PAH showed a signifi-
cant improvement in RV hemodynamics, exercise capa-
city, and functional capacity over 12 weeks of treatment 
with bosentan (125 mg twice daily). Aminotransferase 
levels were elevated in 2 cases, but returned to the base-
line levels with a reduction of dose or after discontinu-
ation of the medication. Therefore, bosentan, 125 mg 
twice daily, is considered a clinically optimal dose of 
treatment and can be employed in clinical practice as a 
valuable treatment option in Korean patients with PAH. 
Given the more frequent elevation in liver enzyme levels 
in comparison with data from Western patients, how-
ever, close monitoring of liver function tests during the 
first few weeks of treatment appears to be mandatory 
for the early detection of this adverse event. 
 
REFERENCES 
1) Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 
336:111-7. 
2) D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with 
primary pulmonary hypertension: results from a national pro-
spective registry. Ann Intern Med 1991;115:343-9. 
3) Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent va-
soconstrictor peptide produced by vascular endothelial cells. Na-
ture 1988;332:411-5. 
4) McLaughlin VV, McGoon MD. Pulmonary arterial hyperten-
sion. Circulation 2006;114:1417-31. 
5) Giaid A, Yanagisawa M, Langleben D, et al. Expression of endo-
thelin-1 in the lungs of patients with pulmonary hypertension. N 
Engl J Med 1993;328:1732-9. 
6) Rubens C, Ewert R, Halank M, et al. Big endthelin-1 and endo-
thelin-1 plasma levels are correlated with severity of primary pul-
monary hypertension. Chest 2001;120:1562-9. 
7) Channnick RN, Simonneau G, Sitbon O, et al. Effects of the dual 
endothelin-receptor antagonist bosentan in patients with pulmo-
nary hypertension: a randomized placebo-controlled study. Lan-
 
 
110·Bosentan Treatment in Koreans 
 
cet 2001;358:1119-23. 
8) Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for 
pulmonary arterial hypertension. N Engl J Med 2002;346:896-
903. 
9) McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-
line bosentan in patients with primary pulmonary hypertension. 
Eur Respir J 2005;25:244-9. 
10) Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and 
treatment of pulmonary arterial hypertension. Eur Heart J 2004; 
25:2243-78. 
11) Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary 
arterial hypertension. N Engl J Med 2004;351:1425-36. 
12) Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Compar-
ative analysis of clinical trials and evidence-based treatment al-
gorithm in pulmonary arterial hypertension. J Am Coll Cardiol 
2004;43(12 Suppl S):81S-8S. 
13) Kim HK, Kim YJ, Park JS, et al. Determinants of the severity of 
functional tricuspid regurgitation. Am J Cardiol 2006;98:236-42.  
14) Sagie A, Schwammenthal E, Padial LR, Vazquez de Prada JA, 
Weyman AE, Levine RA. Determinants of functional tricuspid 
regurgitation in incomplete tricuspid valve closure: Doppler color 
flow study of 109 patients. J Am Coll Cardiol 1994;24:446-53. 
15) Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation 
of right atrial pressure from the inspiratory collapse of the infe-
rior vena cava. Am J Cardiol 1990;66:493-6. 
16) Hinderliter AL, Willis PW 4th, Barst RJ, et al. Effect of long-term 
infusion of prostacyclin (epoprostenol) on echocardiographic 
measures of right ventricular structure and function in primary 
pulmonary hypertension. Circulation 1997;95:1479-86.  
17) Hinderliter AL, Willis PW 4th, Long W, et al. Frequency and prog-
nostic significance of pericardial effusion in primary pulmonary 
hypertension. Am J Cardiol 1999;84:481-4. 
18) Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin 
VV. Medical therapy for pulmonary arterial hypertension: up-
dated ACCP evidence-based clinical practice guidelines. Chest 
2007;131:1917-28. 
19) Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in pa-
tients with class III idiopathic pulmonary arterial hypertension 
treated with first line oral bosentan compared with an historical 
cohort of patients started on intravenous epoprostenol. Thorax 
2005;60:1025-30. 
20) Sasayama S, Kunieda T, Tomoike H, et al. Effects of the en-
dothelin receptor antagonist bosentan on hemodynamics, symp-
toms and functional capacity in Japanese patients with severe 
pulmonary hypertension. Circ J 2005;69:131-7. 
21) Sasayama S, Satoh T, Izumi T, Yoshida S, Kyotani S, Tahara N. 
Long-term trial of bosentan monotherapy for pulmonary arterial 
hypertension in Japanese patients. Curr Med Res Opin 2007;23: 
395-400. 
22) Bossone E, Duong-Wagner TH, Paciocco G, et al. Echocardio-
graphic features of primary pulmonary hypertension. J Am Soc 
Echocardiogr 1999;12:655-62. 
23) Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual 
endothelin-receptor antagonist bosentan in patients with pulmo-
nary hypertension: a randomised placebo-controlled study. Lan-
cet 2001;358:1119-23. 
24) Galié N, Hinderliter AL, Torbicki A, et al. Effects of the oral en-
dothelin-receptor antagonist bosentan on echocardiographic and 
Doppler measures in patients with pulmonary arterial hyperten-
sion. J Am Coll Cardiol 2003;41:1380-6.  
 
 
 
 
